ABBVIE
🇫🇷France
A Phase 2a Study Evaluating the Safety and Efficacy of ABT-981 in Patients With Erosive Hand Osteoarthritis
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-03-10
- Last Posted Date
- 2017-08-11
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 132
- Registration Number
- NCT02384538
Health Related Quality of Life in LCIG Patients and LCIG Eligible Patients Continuing Oral Therapy
Completed
- Conditions
- First Posted Date
- 2015-03-06
- Last Posted Date
- 2020-12-09
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 136
- Registration Number
- NCT02381444
- Locations
- 🇩🇪
Gertrudis-Klinik /ID# 144631, Leun-biskirchen, Germany
🇩🇪Klinikum Altenburger Land /ID# 139643, Altenburg, Germany
🇩🇪Klinik Haag /ID# 137458, Haag, Germany
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Immunomodulators or Anti-TNF Therapy
- First Posted Date
- 2015-02-19
- Last Posted Date
- 2023-12-27
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 220
- Registration Number
- NCT02365649
A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2015-02-19
- Last Posted Date
- 2018-03-30
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 46
- Registration Number
- NCT02365662
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇪🇸Fundacion Jimenez Diaz, Madrid, Spain
Progress at Work - The Impact of Adalimumab on Work Related Productivity in Patients With Rheumatoid Arthritis
Completed
- Conditions
- First Posted Date
- 2015-02-12
- Last Posted Date
- 2021-02-11
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 401
- Registration Number
- NCT02362074
- Locations
- 🇨🇦
Drs. M & W Teo Inc. /ID# 148641, Penticton, British Columbia, Canada
🇨🇦Kur, Vancouver, CA /ID# 135371, Vancouver, British Columbia, Canada
🇨🇦Nexus Clinical Research /ID# 135411, St. John's, Newfoundland and Labrador, Canada
A Study of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Sofosbuvir and Ribavirin in Direct-Acting Antiviral Agent Treatment-Experienced Adults With Chronic Hepatitis C Virus Infection
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-02-05
- Last Posted Date
- 2017-12-20
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 29
- Registration Number
- NCT02356562
A Phase 2 Study to Investigate the Safety, Tolerability and Efficacy of ABT-122 in Subjects With Active Psoriatic Arthritis (PsA) Who Have an Inadequate Response to Methotrexate (MTX)
- First Posted Date
- 2015-01-28
- Last Posted Date
- 2017-08-04
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 240
- Registration Number
- NCT02349451
Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-01-22
- Last Posted Date
- 2020-05-22
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 266
- Registration Number
- NCT02343406
- Locations
- 🇫🇷
Hopital Pitie Salpetriere /ID# 145887, Paris, France
🇮🇹Fondazione IRCCS Istituto Neurologico Carlo Besta /ID# 140395, Milan, Italy
🇫🇷CHU-Hopital Avicenne /ID# 137910, Bobigny, Ile-de-France, France
Observe the Frequency of Extra-Axial Symptoms in Korean Ankylosing Spondylitis (AS) Patients
- First Posted Date
- 2015-01-07
- Last Posted Date
- 2019-01-15
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 201
- Registration Number
- NCT02333383
Real Life Evaluation of Rheumatoid Arthritis Patients in Israel Treated With HUMIRA
Withdrawn
- Conditions
- First Posted Date
- 2014-12-23
- Last Posted Date
- 2016-02-19
- Lead Sponsor
- AbbVie
- Registration Number
- NCT02322723
© Copyright 2024. All Rights Reserved by MedPath